Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALS-008176 Single Ascending Dose Study in Healthy Japanese Adults
NCT02478333Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lumicitabine in respiratory syncytial virus infection (RSV) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 144 hours, Time to Reach Maximum Plasma Concentration at 144 hours and 5 more. Started May 2015; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02478333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478333.